NCT03226678View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions
Warm Autoimmune Hemolytic AnemiaCold Agglutinin Disease
Interventions
DRUG

APL-2

Complement (C3) Inhibitor

Trial Locations (8)

27834

East Carolina University, Greenville

32763

Mid Florida Hematology Oncology, Orange City

33014

Lakes Research, Miami Lakes

37920

University of Tennessee Medical Center, Knoxville

52242

University of Iowa Hospitals, Iowa City

55905

Mayo Clinic, Rochester

90603

American Institute of Research, Whittier

98405

Northwest Medical Specialties, Tacoma

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY

NCT03226678 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | Biotech Hunter | Biotech Hunter